Seres Therapeutics (NASDAQ:MCRB) Shares Pass Above 50-Day Moving Average - What's Next?

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $8.27 and traded as high as $12.18. Seres Therapeutics shares last traded at $11.36, with a volume of 107,170 shares traded.

Analysts Set New Price Targets

Several equities research analysts have issued reports on MCRB shares. Chardan Capital restated a "neutral" rating and issued a $6.00 price target (up from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. Wall Street Zen upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, May 9th. Finally, The Goldman Sachs Group cut their price objective on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a research report on Friday, March 14th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $73.67.

Seres Therapeutics Trading Down 7.8%

The company has a 50 day moving average price of $8.27 and a 200-day moving average price of $12.48. The company has a market cap of $95.51 million, a P/E ratio of -2.35 and a beta of 2.75.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). Equities analysts expect that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in Seres Therapeutics by 15.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock worth $720,000 after buying an additional 117,107 shares during the period. Avantax Advisory Services Inc. grew its holdings in shares of Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 28,500 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Seres Therapeutics by 8.8% in the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company's stock valued at $1,256,000 after acquiring an additional 121,793 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after acquiring an additional 44,461 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 37,866 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.